Related Experiment Video
Updated: Jun 21, 2026
10:25
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Metabolic profiles in patients with chronic hepatitis C: a case-control study
Ching-Sheng Hsu1, Chun-Jen Liu, Chen-Hua Liu
1Division of Gastroenterology, Buddhist Tzu Chi General Hospital, Taipei Branch, Taipei, Taiwan, ROC, d94421001@ntu.edu.tw.
Hepatology International
|August 12, 2009
Summary
Chronic hepatitis C (HCV) infection alters metabolic profiles, affecting lipid levels and increasing adiponectin. These changes vary with alanine aminotransferase (ALT) levels, age, and gender, highlighting complex interactions.
Area of Science:
- Hepatology
- Metabolic Syndrome
- Virology
Background:
- Metabolic profiles in chronic hepatitis C (HCV) patients lack clear clinical implications.
- Metabolic abnormalities associated with HCV require further investigation.
Purpose of the Study:
- To investigate the association between metabolic abnormalities and chronic hepatitis C.
- To analyze serum lipid patterns, fasting blood glucose, and adiponectin in HCV patients.
Main Methods:
- A case-control study involving 500 chronic hepatitis C patients and 536 controls.
- Analysis of demographic and metabolic variables, including serum lipids, glucose, and adiponectin.
- Multiple linear regression was used to assess independent associations.
Main Results:
- HCV patients exhibited higher alanine aminotransferase (ALT) and high-density lipoprotein-cholesterol, but lower total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol compared to controls.
- HCV infection was linked to younger age, female gender, and higher TC in patients with normal ALT, but lower TC and TG in those with abnormal ALT.
- HCV infection was independently associated with higher serum adiponectin levels.
Conclusions:
- Metabolic profiles in chronic hepatitis C are influenced by age, gender, serum adiponectin, and ALT levels.
- The intricate relationship between HCV infection and metabolic profiles warrants further longitudinal research.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...